Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Polynovo ( (AU:PNV) ) has shared an announcement.
PolyNovo’s 2025 Annual Report highlights its strategic focus on expanding global reach and product offerings, particularly with NovoSorb MTX. The company is enhancing its market position by scaling operations and driving growth through innovation, which is expected to benefit stakeholders by improving patient outcomes and increasing market penetration.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo, headquartered in Melbourne, Australia, is a medical technology company specializing in the management of acute and complex wounds. The company offers innovative product solutions such as NovoSorb BTM and NovoSorb MTX, which enhance patient outcomes across a wide range of wounds. PolyNovo has treated over 84,000 patients in 46 countries and is expanding its global presence through new products and clinical indications.
YTD Price Performance: -25.25%
Average Trading Volume: 2,666,783
Technical Sentiment Signal: Hold
Current Market Cap: A$1.05B
Find detailed analytics on PNV stock on TipRanks’ Stock Analysis page.